Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

01/12/2022

Raíra Mesquita Maschmann, Rafaela Gomes De Jesus, Gustavo Werutsky, Taiane Francieli Rebelatto, Geraldo Queiroz, Sergio Daniel Simon, José Bines, Carlos Henrique Escosteguy Barrios & Daniela Dornelles Rosa

DOI: 10.1007/s10549-022-06809-8

Full link: https://pubmed.ncbi.nlm.nih.gov/36586038/

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Send us a message

Cura Project

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Related Posts

In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.”

Moderately hypofractionated post-operative radiation therapy for breast cancer: Preferences amongst radiation oncologists from countries in Latin America and the Caribbean

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018

Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)